(IDeate-PanTumor02) A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors
Principal Investigator (PI)
Clinical Trials.gov ID
Key Eligibility
Protocol #
SPONSOR
